Articles tagged with: Cure
Featured, Headline, News »
Is gene therapy too expensive and impractical to form the basis for a cure for HIV, or is it a promising technique with a proven track record that has the specificity required for a cure?
This question was debated by researchers at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS 2011) in Rome last month.
Gene therapy is an experimental approach that is currently in early stages of clinical testing. Gene therapy involves modifying a person’s DNA (the genetic information in cells) so that it…
News »
IAS 2011 Conference Begins July 17 In Rome – The sixth International AIDS Society (IAS) conference will take place in Rome July 17 to 20. The conference, which is held every two years, is the one of the largest worldwide on HIV and AIDS. Topics will include new treatments and treatment possibilities for HIV, research and management of side effects and complications of HIV and antiretroviral therapy, and progress toward a cure. Conference organizers expect around 5,000 attendees. The AIDS Beacon will be providing coverage of conference results. For more information, please see the IAS 2011 conference website.
NIAID Makes Five Year, Multi-Million Dollar Grants Toward HIV Cure Research – The National Institute of Allergy and Infectious Diseases (NIAID) announced today that it has granted more than $14 million per year for up to five years toward research for a cure for HIV. The new grants, part of the Martin Delaney Collaboratory of funding toward an HIV cure, focus on studying and eliminating reservoirs of latent HIV (HIV that lies dormant during antiretroviral therapy until treatment is stopped). Recipients include the Fred Hutchinson Cancer Research Center, the University of North Carolina at Chapel Hill, the University of California, San Francisco, and the Vaccine & Gene Therapy Institute of Florida. For more information please see the NIAID press release.
Theratechnologies Applies For Marketing Approval Of Egrifta In Israel – Theratechnologies, via its partner Sanofi, has applied for marketing approval of Egrifta (tesamorelin) in Israel. If approved, Egrifta will be the first drug in Israel to treat lipodystrophy, a condition of abnormal fat distribution that is a side effect of certain anti-HIV medications. Based on average approval times in Israel, a decision would be expected in mid-2013. Egrifta was approved in the U.S. in November of last year, and Theratechnologies’ partners have since applied for approval in Europe and Canada. For more information, please see the Theratechnologies press release.
Featured, Headline, News »
This Sunday will mark the 30th anniversary of the first reports of AIDS in the United States. This week, physicians, policy makers, and the HIV-positive community have paused to reflect on the progress that has been made in combating the disease, as well as the long road still ahead toward eradicating the virus. The anniversary also provides a time to remember the lives that have been lost to AIDS, both in the U.S. and around the world.
“Many of us have been touched by the disease, be it a family…
Headline, News »
This article is the fourth in a four-part series that investigates current research toward finding a cure for HIV, including advances, promising treatment strategies, and barriers to reaching a cure. Part 1 discusses general types of HIV cures. Part 2 discusses specific strategies for targeting latent HIV. Part 3 discusses gene therapy and therapeutic vaccines. Part 4 discusses barriers to obtaining a cure.
Although researchers are getting closer to finding a cure for HIV and have a number of promising avenues to pursue, there are still a…
Headline, News »
This article is the third in a four-part series that will investigate current research toward finding a cure for HIV, including advances, promising treatment strategies, and barriers to reaching a cure. Part 1 discusses general types of HIV cures. Part 2 discusses specific strategies for targeting latent HIV. Part 3 discusses gene therapy and therapeutic vaccines. Part 4 discusses barriers to obtaining a cure.
As researchers become more optimistic that a cure for HIV will be found, they are pursuing a number of different possible strategies, including…